Global Cell and Gene Therapy Market to Reach US$ 43.0 Billion by 2028, Stimulated by Significant Growth in Biotechnology Field

July 14, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Cell and Gene Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global cell and gene therapy market size reached US$ 15.9 Billion in 2022. Cell and gene therapy is a revolutionary branch of medical science, engineered to treat, prevent, and potentially eradicate genetic diseases and various types of cancers. It revolves around modifying or manipulating the cells and genes in the human body to fight or manage diseases. It involves the administration of living whole cells into a patient for the treatment of a disease, whereas gene therapy seeks to alter or replace genes to treat or prevent disease. This therapy is used to treat conditions where conventional treatments and medicines are not very effective. Currently, cell and gene therapies are at the forefront of medical research, with numerous trials being conducted worldwide to explore their therapeutic potential in a wide array of disease categories.


Global Cell and Gene Therapy Market Trends:

The global cell and gene therapy market is presently witnessing a significant growth, driven by the increasing prevalence of cancer and genetic diseases, which intensifies the demand for more effective treatments. This, coupled with the growing understanding and awareness about the potential of these therapies in addressing, such conditions, is propelling the market. Additionally, the ongoing advancements in biotechnology and molecular biology, which have led to more efficient and safer therapeutic techniques, are adding impetus to the market expansion. Additionally, the incorporation of artificial intelligence and machine learning in the development and delivery of these therapies is another notable trend fueling the market growth. Moreover, the rise in investments by pharmaceutical and biotechnological firms, driven by encouraging clinical trial results and increasing regulatory approvals, is significantly supporting the demand. Apart from this, the growing emphasis on personalized medicine, with cell and gene therapies playing a key role, which is contributing to the market. Furthermore, the advent of CRISPR technology for gene editing and next-generation sequencing techniques is creating a positive market outlook. Looking forward, the market value is projected to reach US$ Looking forward, the market value is projected to reach US$ 43.0 Billion by 2028, expanding at a CAGR of 17.4% during 2023-2028.


Market Summary:

  • Based on the therapy type, the market has been segmented into cell therapy (stem cell [pluripotent, cancer, and adult stem cells]), non-stem cell [t cells, natural killer, and others]), and gene therapy.
  • On the basis of the indication, the market has been divided into cardiovascular disease, oncology disease, genetic disorder, infectious disease, neurological disorder, and others. Among these, oncology disorder accounts for the largest market share.
  • Based on the delivery mode, the market has been segregated into in-vivo and ex-vivo.
  • On the basis of the end user, the market has been segmented into hospitals, cancer care centers, pharmaceutical & biotechnology companies, and others. Presently, hospitals exhibit a clear dominance.
  • Region-wise, the market has been segmented into North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. Currently, North America holds the leading position in the market.
  • The competitive landscape of the market has also been examined, with some of the key players being Amgen Inc., Biogen, Bluebird bio, Inc., Bristol-Myers Squibb, Gilead Science, Kolon TissueGene Inc., Orchard Therapeutics plc., Pfizer Inc, Renova Therapeutics, and Spark Therapeutics, Inc.


Report Scope:

Report Features Details
Base Year of the Analysis 2022
Historical Period 2017-2022
Forecast Period 2023-2028
Units US$ Billion
Therapy Types Covered
  • Cell Therapy: Stem Cell (Pluripotent Stem Cell, Cancer Stem Cell, Adult Stem Cell), Non-Stem Cell (T Cells, Natural Killer, Others)
  • Gene Therapy
Indications Covered Cardiovascular Disease, Oncology Disorder, Genetic Disorder, Infectious Disease, Neurological Disorder, Others
Delivery Modes Covered In-Vivo, Ex-Vivo
End Users Covered Hospitals, Cancer Care Centers, Pharmaceutical & Biotechnology Companies, Others
Regions Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., Biogen , Bluebird bio, Inc., Bristol-Myers Squibb, Gilead Science, Kolon TissueGene Inc., Orchard Therapeutics plc., Pfizer Inc, Renova Therapeutics, and Spark Therapeutics, Inc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 5499
Five User License: US$ 6999
Corporate License: US$ 8499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.


Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Cell and Gene Therapy Market to Reach US$ 43.0 Billion by 2028, Stimulated by Significant Growth in Biotechnology Field
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More